文献速递血栓与止血

癌症患者静脉血栓栓塞症的人群队列研究

Venous thromboembolism in cancer patients: a population-based cohort study.
PubMed 文献 · Blood · 2021-01-01

该研究基于丹麦医学登记库,纳入1997至2017年首次诊断癌症的499 092例患者及1 497 276名无癌症对照,计算诊断后6和12个月VTE累积发病率。癌症患者12个月VTE累积发病率为2.3%,对照组为0.35%(HR 8.5),且癌症队列12个月发病率从1997年1.0%升至2017年3.4%。

要点

  • 癌症患者12个月VTE累积发病率为2.3%,显著高于一般人群的0.35%。
  • 既往VTE、远处转移及化疗、蛋白激酶抑制剂、抗血管生成治疗、免疫治疗均增加VTE风险。
  • 癌症患者12个月VTE发病率从1997年1.0%升至2017年3.4%,与生存改善及CT、化疗、靶向治疗使用增加平行。

核心结论

  • 癌症患者VTE风险稳步增加,约为一般人群的九倍。

研究设计与样本

  • 基于丹麦医学登记库的人群队列研究,纳入1997至2017年首次诊断癌症的499 092例患者,匹配1 497 276名无癌症对照。

主要发现

  • 癌症患者诊断后12个月VTE累积发病率为2.3%(95%CI 2.2%-2.3%),对照组为0.35%(95%CI 0.34%-0.36%),HR为8.5(95%CI 8.2-8.8)。
  • 癌症患者VTE重要风险因素包括既往VTE(SHR 7.6,95%CI 7.2-8.0)、远处转移(SHR 3.2,95%CI 2.9-3.4)、化疗(SHR 3.4,95%CI 3.1-3.7)、蛋白激酶抑制剂(SHR 4.1,95%CI 3.4-4.9)、抗血管生成治疗(SHR 4.4,95%CI 3.8-5.2)和免疫治疗(SHR 3.6,95%CI 2.8-4.6)。
  • 癌症队列12个月VTE发病率从1997年1.0%(95%CI 0.9%-1.2%)增至2017年3.4%(95%CI 2.9%-4.0%),与12个月生存改善及CT扫描、化疗和靶向治疗使用增加平行。

临床怎么用

  • 对癌症患者应结合既往VTE、远处转移及化疗、靶向治疗、免疫治疗等风险因素评估VTE风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The incidence of venous thromboembolism (VTE) in cancer patients may have changed in the past decade, possibly due to novel cancer therapies, improved survival, and high-resolution imaging. Danish medical registries were used to identify 499 092 patients with a first-time cancer diagnosis between 1997 and 2017, who were matched to 1 497 276 comparison individuals without cancer from the general population. We computed cumulative incidences of VTE 6 and 12 months after the diagnosis/index date. Hazard ratios (HRs) were calculated using Cox regression. Risk factors were examined by computing subdistribution hazard ratios (SHRs) in a competing-risk analysis. Cumulative incidence of VTE 12 months after the cancer diagnosis/index date was 2.3% (95% confidence interval [CI], 2.2% to 2.3%) in the cancer cohort and 0.35% (95% CI, 0.34% to 0.36%) in the comparison cohort (HR, 8.5; 95% CI, 8.2-8.8). Important risk factors for cancer patients were prior VTE (SHR, 7.6; 95% CI, 7.2-8.0), distant metastasis (SHR, 3.2; 95% CI, 2.9-3.4), and use of chemotherapy (SHR, 3.4; 95% CI, 3.1-3.7), protein kinase inhibitors (SHR, 4.1; 95% CI, 3.4-4.9), antiangiogenic therapy (SHR, 4.4; 95% CI, 3.8-5.2), and immunotherapy (SHR, 3.6; 2.8-4.6). Twelve-month incidence in the cancer cohort increased from 1.0% (95% CI, 0.9% to 1.2%) in 1997 to 3.4% (95% CI, 2.9% to 4.0%) in 2017, which was paralleled by improved 12-month survival and increased use of computed tomography scans, chemotherapy, and targeted therapies. In conclusion, the risk of VTE in cancer patients is increasing steadily and is ninefold higher than in the general population.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Mulder FI, Horváth-Puhó E, van Es N, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021. PMID: 33171494. doi:10.1182/blood.2020007338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。